Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.
Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, Newbold KL, Harrington KJ, Nutting CM. Miah AB, et al. Among authors: clark ch. Br J Cancer. 2015 Jan 6;112(1):32-8. doi: 10.1038/bjc.2014.553. Epub 2014 Dec 4. Br J Cancer. 2015. PMID: 25474250 Free PMC article. Clinical Trial.
Implementation of IMRT in the radiotherapy department.
McNair HA, Adams EJ, Clark CH, Miles EA, Nutting CM. McNair HA, et al. Among authors: clark ch. Br J Radiol. 2003 Dec;76(912):850-6. doi: 10.1259/bjr/19737738. Br J Radiol. 2003. PMID: 14711771 Review.
Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.
Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, Nutting CM, PARSPORT Trial Management Group. Guerrero Urbano MT, et al. Among authors: clark ch. Clin Oncol (R Coll Radiol). 2007 Oct;19(8):604-13. doi: 10.1016/j.clon.2007.07.001. Epub 2007 Aug 13. Clin Oncol (R Coll Radiol). 2007. PMID: 17706404 Clinical Trial.
Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer.
Clark CH, Miles EA, Urbano MT, Bhide SA, Bidmead AM, Harrington KJ, Nutting CM; UK PARSPORT Trial Management Group collaborators. Clark CH, et al. Br J Radiol. 2009 Jul;82(979):585-94. doi: 10.1259/bjr/31966505. Epub 2009 Mar 30. Br J Radiol. 2009. PMID: 19332518 Clinical Trial.
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, Adams E, Hansen V, Clark C, Miles E, McNair H, Nutting C, Parker C, Eeles R, Huddart R, Horwich A, Dearnaley DP. Guerrero Urbano T, et al. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44. doi: 10.1016/j.clon.2010.01.005. Epub 2010 Feb 19. Clin Oncol (R Coll Radiol). 2010. PMID: 20171852 Clinical Trial.
Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
Naismith O, Mayles H, Bidmead M, Clark CH, Gulliford S, Hassan S, Khoo V, Roberts K, South C, Hall E, Dearnaley D; CHHiP Investigators. Naismith O, et al. Among authors: clark ch. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):611-620. doi: 10.1016/j.clon.2019.05.009. Epub 2019 Jun 11. Clin Oncol (R Coll Radiol). 2019. PMID: 31201110 Clinical Trial.
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J, Mascarenhas L, Syngal S, Ukaegbu C, Side L, Thomas T, Barwell J, Teixeira MR, Izatt L, Suri M, Macrae FA, Poplawski N, Chen-Shtoyerman R, Ahmed M, Musgrave H, Nicolai N, Greenhalgh L, Brewer C, Pachter N, Spigelman AD, Azzabi A, Helfand BT, Halliday D, Buys S, Ramon Y Cajal T, Donaldson A, Cooney KA, Harris M, McGrath J, Davidson R, Taylor A, Cooke P, Myhill K, Hogben M, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Dias A, Dudderidge T, Eccles DM, Green K, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lilja H, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra AV, Moynihan C, Ni Raghallaigh H, Rennert G, Collier R; IMPACT Study Collaborators; Offman J, Kote-Jarai Z, Eeles RA. Bancroft EK, et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. doi: 10.1016/S1470-2045(21)00522-2. Epub 2021 Oct 19. Lancet Oncol. 2021. PMID: 34678156 Free PMC article.
146 results